Tris Pharma, a commercial-stage biopharmaceutical company focused on developing therapies for unmet medical needs, has announced two new partnerships with Calm Health and ADHD Central to provide additional support to people living with Attention-Deficit/Hyperactivity Disorder (ADHD).

The collaborations are designed to extend support beyond prescription treatment by giving eligible patients and their caregivers access to resources focused on mental well-being, organisation, self-management and day-to-day productivity.

Under the partnership with Calm Health, eligible patients starting treatment with Dyanavel XR will receive three months of complimentary access to the clinical digital mental health platform and self-care app. Developed with input from psychologists, Calm Health provides personalised action plans and evidence-based self-care programmes, including ADHD-specific resources aimed at helping users develop healthy habits, strengthen self-management skills and navigate everyday challenges associated with ADHD.

Manesh Naidu, chief commercial officer of Tris Pharma, said, “Effective ADHD management often requires more than medication alone. He added that the partnerships are intended to provide patients with tools that can support mental well-being and daily organisation as they begin a new treatment.

Tris Pharma has also partnered with ADHD Central, which develops tactile, screen-free and visual organisational tools designed specifically for people with ADHD. Founded by Graham Meckling and Claire Butterfield, ADHD Central focuses on practical products that help individuals organise daily responsibilities while reducing dependence on digital devices.

As part of the collaboration, patients and caregivers will be introduced to tools such as ON TRACK Cards, a visual task-management system designed to reduce digital overwhelm and provide a simplified approach to planning and managing daily activities. The initiative aims to support focus, productivity and routine-building alongside conventional treatment.

The partnerships form part of Tris Pharma’s broader effort to improve the treatment experience for people with ADHD, particularly those whose symptoms may not be optimally managed. By connecting patients and caregivers with mental health resources and practical organisational strategies, the company aims to provide a more comprehensive support ecosystem around ADHD care.

Dyanavel XR is a long-acting amphetamine-based treatment indicated for the treatment of ADHD in patients aged six years and older. The treatment is designed to provide symptom control throughout the day and offers an option for patients requiring an individualised approach to ADHD management. Its use is not recommended in paediatric patients younger than six years because of higher plasma exposure and a greater incidence of certain adverse reactions observed in this age group.

Tris Pharma is a privately held biopharmaceutical company that applies proprietary technologies and drug development capabilities across ADHD, pain, addiction and central nervous system disorders. The company markets a portfolio of ADHD products and is advancing a pipeline of differentiated drug candidates.

Calm Health, developed by the makers of Calm, provides evidence-based digital mental health programmes through employers, health plans and healthcare providers. ADHD Central focuses on screen-free, analogue productivity tools, including its flagship ON TRACK Cards, designed to help people organise tasks, reduce digital distractions and build sustainable routines.